Urotronic has raised $6.1 million in an equity offering involving 21 investors, according to a document filed with the SEC this week. The Minnesota-based company has not publicly stated how it plans to spend its newly-acquired funds. Urotronic is developing a drug-coated balloon catheter designed to treat urethral strictures in men. Get the full story at our sister […]
Minneapolis-based Urotronic said this week that the FDA approved an investigational device exemption trial for its Optilume drug-coated balloon catheter, which is designed to treat urethral strictures in men. The 200-patient pivotal trial is slated to start enrolling participants immediately. Get the full story at our sister site, Drug Delivery Business News.
Urotronic is launching a feasibility trial of its drug-coated balloon in men with narrowed urethras, according to StarTribune. The Plymouth, Minn.-based company’s Optilume device is inserted into a patient’s urethra and then inflates to dilate the urethra, allowing urine to leave the patient’s bladder. Get the full story at our sister site, Drug Delivery Business News.
The former vice president of R&D for drug-coated balloon maker Lutonix, Christopher Barry, yesterday pleaded guilty to a single count of trade secret theft in federal court in Minneapolis. Barry, who left Lutonix in 2015 to become CEO of Urotronic, admitted to downloading 6 files in April 2015 containing trade secrets about the development of […]